NCT01252953View on ClinicalTrials.gov

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30,449

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2037

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

Anacetrapib

tablet, 100mg daily

DRUG

Placebo anacetrapib

tablet, 1 tablet daily

Trial Locations (1)

OX3 7LF

CTSU, University of Oxford, Oxford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Oxford

OTHER